Eiger BioPharmaceuticals (STU:72C) EBIT: €-34.24 Mil (TTM As of Dec. 2023)


STU:72C Eiger BioPharmaceuticals Inc STU:72C
10 GF Score
Price €6.18
View Full Analysis

What is Eiger BioPharmaceuticals EBIT?

Eiger BioPharmaceuticals STU:72C 10 EBIT is €-34.24 Mil as of Dec. 2023. GuruFocus rates STU:72C with a GF Score™ of 10/100.

Eiger BioPharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was €-26.27 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was €-34.24 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Eiger BioPharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 was -212.23%. Eiger BioPharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -4,540.54%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Eiger BioPharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -484.02%.

Eiger BioPharmaceuticals  (STU:72C) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Eiger BioPharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-54.18 * ( 1 - 0% )/( (7.488 + 43.569)/ 2 )
=-54.18/25.5285
=-212.23 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=66.786 - 9.817 - ( 49.481 - max(0, 15.426 - 65.057+49.481))
=7.488

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=35.603 - 6.197 - ( 23.328 - max(0, 48.861 - 34.698+23.328))
=43.569

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Eiger BioPharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-52.534/( ( (1.001 + max(0.446, 0)) + (0.575 + max(0.29200000000001, 0)) )/ 2 )
=-52.534/( ( 1.447 + 0.86700000000001 )/ 2 )
=-52.534/1.157
=-4,540.54 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.429 + 1.013 + 11.134) - (9.817 + 0 + 5.313)
=0.446

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.542 + 1.427 + 8.401) - (6.197 + 0 + 4.881)
=0.29200000000001

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Eiger BioPharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-34.235/7.073
=-484.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiger BioPharmaceuticals EBIT Related Terms

Eiger BioPharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Eiger BioPharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiger BioPharmaceuticals EBIT Chart

Eiger BioPharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -60.16 -50.52 -26.81 -87.43 -63.72

Eiger BioPharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.38 -47.14 -37.70 -26.27 -7.97

STU:72C vs EDSA, SIGY, EVLO: EBIT Comparison

For the Biotechnology subindustry, Eiger BioPharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eiger BioPharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eiger BioPharmaceuticals's EV-to-EBIT falls into.


STU:72C
10GF Score
Eiger BioPharmaceuticals Inc STU:72C
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eiger BioPharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-34.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-34.24 Mil mean?
Eiger BioPharmaceuticals (STU:72C) has a EBIT of €-34.24 Mil as of Dec. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eiger BioPharmaceuticals.
Is Eiger BioPharmaceuticals' EBIT too high?
Eiger BioPharmaceuticals' current EBIT is €-34.24 Mil. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Eiger BioPharmaceuticals' EBIT compare to EDSA and SIGY?
Eiger BioPharmaceuticals' EBIT of €-34.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eiger BioPharmaceuticals. Eiger BioPharmaceuticals's current EBIT is €-34.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiger BioPharmaceuticals stock overvalued right now?
Eiger BioPharmaceuticals (STU:72C) has a current EBIT of €-34.24 Mil. The current EBIT is €-34.24 Mil. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current EBIT is €-34.24 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eiger BioPharmaceuticals Business Description

Address 2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
10GF Score

Get the complete analysis for STU:72C

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.18
Price